A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Tucatinib
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: Seagen Inc.